RIGL was selected by the FATTORIALE screen because it combines commercial product growth, positive net income, low balance-sheet leverage and strong recent price momentum. The independent DD does not treat the quality tag as a conclusion: base fair value is moderately above spot, while high short interest and product concentration leave meaningful execution risk.
The bridge implies operating EV of about $1.09B before cash and tax assets, or roughly 2.9x a $373M FY2027 revenue base. Cross-check: 12.5x StockAnalysis FY2027 EPS estimate of $4.94 gives $61.75, within 1% of the bridge. The base FV is 2.4% below the StockAnalysis $63.00 target, 4.3% below ChartMill's $64.26 mean target, and 4.2% above MarketBeat's $59.00 target. Sensitivity: each 0.5x change in the portfolio EV/sales multiple changes FV by about $9-$10 per share. Not investment advice.
| Component | Assumption | USD/share |
|---|---|---|
| TAVALISSE franchise EV | $220M FY2027E sales x 3.2x EV/sales / 18.68M shares | +37.69 |
| REZLIDHIA franchise EV | $50M FY2027E sales x 3.4x EV/sales / 18.68M shares | +9.10 |
| GAVRETO franchise EV | $40M FY2027E sales x 2.0x EV/sales / 18.68M shares | +4.28 |
| VEPPANU launch option | 50% probability x $45M FY2027E sales x 4.0x EV/sales / 18.68M shares | +4.82 |
| R289 clinical option | 20% probability x $150M lower-risk MDS platform value / 18.68M shares | +1.61 |
| Net cash | ($95.3M cash and short-term investments - $40.0M debt) / 18.68M shares | +2.96 |
| Tax asset value | 25% probability x $238.1M deferred tax asset / 18.68M shares | +3.19 |
| Concentration and execution reserve | -$40M reserve for product concentration, reimbursement and launch execution / 18.68M shares | -2.14 |
| FV base case | Explicit sum: 37.69 + 9.10 + 4.28 + 4.82 + 1.61 + 2.96 + 3.19 - 2.14 | 61.51 |
The short base is large enough to amplify upside on clean execution, but it also flags investor skepticism around sustainability of 2025 profitability, pipeline spending and commercial launch risk.
| Item | FY2023 | FY2024 | FY2025 | FY2026E | Guidance 2026 |
|---|---|---|---|---|---|
| Total revenue | $116.9M | $179.3M | $294.3M | $305.7M | $285-295M company guide, excluding VEPPANU |
| Product sales | $104.3M | $144.9M | $232.0M | $255-265M | Company guide |
| Operating income | -$20.5M | $24.2M | $125.5M | $82.7M | Consensus operating estimate |
| Net income | -$25.1M | $17.5M | $367.0M | $61.7M | FY2025 includes $245.9M non-cash tax benefit |
| Operating cash flow | -$5.7M | $31.5M | $75.7M | $26.0M FCF est. | Consensus FCF estimate |
| Metric | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|---|
| Revenue ($M) | 101.7 | 69.5 | 69.8 | 58.8 | 78.7 |
| Gross margin % | 95.6% | N/D | N/D | 92.2% | 89.2% |
| Net income ($M) | 59.6 | 27.9 | 268.1 | 8.7 | 17.3 |
| End-of-period cash ($M) | N/D | N/D | 155.0 | 146.7 | 95.3 |
Business model - commercial hematology/oncology platform
TAVALISSE ~$200-220M FY2027E revenue anchor ramping Largest franchise. Q2 2026 sales were $47.4M, up 18% YoY. Main risk is mature-market persistence and payer pressure. REZLIDHIA ~$45-55M FY2027E growth product ramping Q2 2026 sales were $8.9M, up 27% YoY. It adds oncology depth but is still smaller than TAVALISSE. GAVRETO ~$35-45M FY2027E mature product softening Q2 2026 sales were $10.7M, down 10% YoY. The model applies a lower multiple because growth is weaker. VEPPANU ~$30-50M FY2027E launch case to prove Approved PROTAC in breast cancer. U.S. availability began in August 2026 after a $70M upfront payment to Arvinas/Pfizer. R289 Option value, no commercial revenue yet clinical IRAK1/4 inhibitor in lower-risk MDS. Dose expansion enrollment and Phase 2 dose selection are expected in H2 2026.
Legal, regulatory and risk analysis
SWOT analysis
- +Commercial-stage platform with multiple marketed products.
- +Positive H1 2026 net income and operating cash flow.
- +Low leverage and pro forma debt reduction after July repayment.
- +Analyst targets cluster above the current price.
- −High short interest and high stock volatility.
- −TAVALISSE concentration still drives a large share of franchise value.
- −FY2025 net income quality distorted by tax accounting.
- −No buyback support identified.
- →VEPPANU launch can widen the commercial base in 2027.
- →R289 year-end data could create pipeline optionality.
- →Short-covering risk if Q3/Q4 execution confirms guidance.
- →International milestones can add episodic contract revenue.
- !Product-level deceleration would compress the sales multiple.
- !Launch spending could cut FY2026-FY2027 EPS below consensus.
- !Clinical disappointment may remove optionality currently embedded in analyst targets.
- !Healthcare risk appetite may rotate away from small-cap biopharma.
Summary by assessment area
- Cash generation and low debt support the quality screen.
- FY2025 accounting benefit should not be capitalized blindly.
- Base FV of $61.50 implies about 26% upside from $48.67.
- Consensus targets broadly validate the bridge, but the margin of safety is not extreme.
- Q3 earnings, VEPPANU launch evidence and R289 data are the next checks.
- High short interest makes misses unusually punitive.
Sources: Rigel Q2 2026 earnings release and SEC 8-K filed Aug. 4, 2026; Rigel Q1 2026 earnings release filed May 5, 2026; Rigel FY2025 Form 10-K filed Mar. 3, 2026; Rigel investor relations event calendar checked Sep. 6, 2026; StockAnalysis overview, statistics, forecast, market-cap and peer pages checked Sep. 5-6, 2026; ChartMill RIGL analyst forecast page checked Sep. 6, 2026; MarketBeat RIGL analysis and short-interest pages updated around Sep. 4, 2026; ChartExchange and Bloomberg Linea quote cross-checks. Price row used: RIGL $48.67, close Sep. 4, 2026; market cap ~$909.15M; 52W range $24.95-$52.24; shares outstanding 18.68M; price x shares = ~$909.1M, matching reported market cap within rounding. Short interest: 3.20M shares, 17.1% of shares outstanding and 21.6% of float, Aug. 14, 2026 settlement. This document is for informational purposes only and does not constitute financial or investment advice.